Capital Empowerment, A New Chapter
In early 2025, Medgen Life Science completed its A+ round of funding totaling tens of millions of RMB, laying a solid foundation for innovation, earning trust through quality, and expanding horizons through collaboration.
Product Innovation, Leading Technological Breakthroughs
PoroGraft® Oral Bone Graft Material Receives NMPA Class III Certification
PoroGraft® — China's first domestically developed porcine-derived xenogeneic bone graft material — received NMPA Class III medical device certification, filling a critical gap in China's oral bone grafting field.
BoneSwift™ Injectable Bone Repair Material Gains Spinal Indication
BoneSwift™ injectable bone repair material received NMPA Class III spinal certification (Registration No. 20253131673), adding spinal bone defect filling as a new indication. This expands its clinical applications from extremity trauma repair to load-bearing spinal reconstruction.
Included in the Shenzhen First-Batch New Materials Catalog
Medgen's bone repair materials were selected for the Shenzhen First-Batch New Materials Catalog, marking a major breakthrough in the company's original biomaterial R&D capabilities.
Strategic Partnerships, Building an Industry Ecosystem
- Medgen × Sanyou Medical: Focused on building a supply chain system for pre-filled bone repair materials, integrating strengths in raw material processing and distribution channels.
- Medgen × Qiantang Longyue: Jointly exploring the convergence of biomaterials and precision medicine to develop next-generation intelligent bone repair materials.
Going Global
2025 was a pivotal year for Medgen's internationalization strategy:
- BSI ISO 13485 Quality Management System Certification achieved, with R&D, production, and service systems fully meeting international regulatory standards
- BoneSwift™ received Vietnam Class D certification, officially launching the company's global journey
- PoroGraft® received Vietnam Class D certification, establishing a dual-engine strategy across orthopedics and dental
- PRP System received Vietnam Class C and Indonesia Class B certifications, accelerating Southeast Asian market penetration
Industry Recognition
- Co-authored CSBM group standards for hydroxyapatite/collagen aesthetic regenerative injection materials, advancing from standard follower to rule maker
- Recognized as a Shenzhen "Specialized, Refined, Distinctive, and Novel" (SRDN) SME by the local government
- Named a 2025 Quality, Safe, and Reliable Medical Aesthetics Service Provider by the Shenzhen Association of Plastic Surgery
Looking Ahead to 2026
Standing at a new starting point, Medgen will continue to deepen its focus on natural bone repair materials, accelerate core technology iteration and global market expansion, and strengthen supply chain innovation — contributing Chinese wisdom and solutions to global healthcare.